On May 20, 3SBio announced that it had signed an exclusive licensing agreement with Pfizer, granting Pfizer the exclusive rights to develop, produce, and commercialize its independently developed breakthrough PD-1/VEGF bispecific antibody SSGJ-707 worldwide (excluding mainland China). At the same time, it retained the relevant rights of the product in mainland China and granted Pfizer the option to commercialize the product in mainland China.

The total amount of this cooperation is as high as US$6.05 billion, including an upfront payment of US$1.25 billion and development, regulatory approval and sales milestone payments of up to US$4.8 billion. In addition, Pfizer will subscribe to 3SBio's common stock worth US$100 million.

SSGJ-707 is a bispecific antibody targeting PD-1/VEGF independently developed by 3SBio based on its proprietary #CLF2 platform. In the Phase II clinical phase analysis, it demonstrated excellent objective response rate (ORR) and disease control rate (DCR) in the treatment of patients with non-small cell lung cancer (NSCLC). Whether used alone or in combination with chemotherapy, it has significant anti-tumor activity and good safety, and is considered to be a best-in-class potential drug.

In April this year, SSGJ-707 was recognized as a breakthrough therapy by the National Medical Products Administration, and its indication is first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive PD-L1 expression. Previously, the drug has obtained IND approval from the FDA, and in addition to non-small cell lung cancer, its clinical research in the fields of colorectal cancer and gynecological tumors is also underway.

Preclinical studies have shown that SSGJ-707 exhibits superior activity to its counterparts. In the first-line treatment of PD-L1-positive NSCLC, the ORR of the 10 mg/kg dose group was as high as 70.8%, the DCR was as high as 100%, and the incidence of grade 3 and above side effects was 23.50%.

https://news.yaozh.com/archive/45489.html